Oxybutynin: an overview of the available formulations.
Ther Clin Risk Manag
; 2(1): 19-24, 2006 Mar.
Article
em En
| MEDLINE
| ID: mdl-18360578
ABSTRACT
Overactive bladder (OAB) is a common problem presented to by physicians. Standard treatment with antimuscarinic medication is directed at suppressing involuntary detrusor contractions by blocking the binding of acetylcholine to muscarinic receptors in the bladder. Oxybutynin chloride is the first of several antimuscarinic medications to be marketed for OAB. Although efficacious for treating OAB symptoms, the side effects and suboptimal dosing regimen decrease its utility. To improve patient compliance and tolerability, alternative delivery systems for oxybutynin have subsequently been developed and include a once-daily formulation and a transdermal system. The currently available formulations of oxybutynin are the subject of this review.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Ther Clin Risk Manag
Ano de publicação:
2006
Tipo de documento:
Article
País de afiliação:
Estados Unidos